Irfan Ahmad, MD
Internal Medicine · Woonsocket, RINPI 1063460426
Payments from drug & device makers
Across 253 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$790
- Pfizer$619
- AstraZeneca$363
- AbbVie$342
- Johnson & Johnson$279
- Boehringer Ingelheim$278
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,27098%
- Education$1042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 53 | $790 |
| Pfizer | 38 | $619 |
| AstraZeneca | 21 | $363 |
| AbbVie(2 entities) | 17 | $342 |
| Johnson & Johnson | 17 | $279 |
| Boehringer Ingelheim | 16 | $278 |
| Novo Nordisk | 12 | $202 |
| Abbott | 8 | $170 |
| Teva Pharmaceuticals USA, Inc. | 8 | $141 |
| Exact Sciences | 6 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $102 |
| Astellas Pharma US Inc | 2 | $102 |
| Sanofi-aventis U.S. LLC | 6 | $100 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84 |
| Novartis | 5 | $77 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $54 |
| Merck | 3 | $45 |
| Lilly USA, LLC | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 1 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $32 |
| Bayer | 2 | $30 |
| Sumitomo Pharma America, Inc. | 2 | $27 |
| Genentech USA, Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| BD | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $19 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$4,374 in reported general payments places this provider in the 90th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 109 | $91,505 |
| EliquisApixaban | 122 | $83,135 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $67,777 |
| OzempicSemaglutide | 29 | $28,442 |
| RybelsusSemaglutide | 15 | $27,600 |
| XareltoRivaroxaban | 22 | $24,089 |
| TrulicityDulaglutide | 19 | $23,982 |
| Bydureon BciseExenatide Microspheres | 13 | $10,158 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,004 |
| Atorvastatin Calcium | 600 | $6,984 |
| Rosuvastatin Calcium | 338 | $6,982 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,564 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,441 |
| FarxigaDapagliflozin Propanediol | 11 | $6,433 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $278 | $91,505109 claims |
| PfizerEliquis | $619 | $83,135122 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $790 | $81,624150 claims |
| Novo NordiskOzempic, Rybelsus | $202 | $56,04244 claims |
| Lilly USA, LLCTrulicity, Insulin Lispro | $37 | $25,11936 claims |
| Johnson & JohnsonXarelto | $279 | $24,08922 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $363 | $12,99722 claims |
| AbbVieSynthroid | $342 | $2,47533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Woonsocket
- Greigstone YearwoodWoonsocket$7K
- David FriedEast Greenwich$37.2M
- Gregory AllenCranston$12.2M
- Kathleen GordonJohnston$1.1M
- William BeliveauJohnson$962K
- Scott WilsonCumberland$907K
- Aaron SamuelsProvidence$751K
- Frank D'alessandroLincoln$541K
- Andrew HsuProvidence$409K
- Heinrich ElinzanoProvidence$396K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.